Document Detail


Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.
MedLine Citation:
PMID:  15380342     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Myelodysplastic syndrome (MDS) comprises a spectrum of heterogeneous diseases. Most patients present with ineffective hematopoiesis. The pathophysiology involves immune-mediated effects, cytokine dysregulation, and apoptosis, among others. We treated 14 transfusion-requiring patients with MDS, 10 with refractory anemia (RA) and four with RA with excess blasts (RAEB) with a 4-day course of antithymocyte globulin (ATG) followed by intermittent etanercept for 4 months. Among 13 evaluable patients, five are red blood cell and platelet transfusion independent for intervals extending beyond 2 years, and two have normalized their peripheral blood parameters. One additional patient showed a transient rise of platelet and neutrophil counts, for an overall response rate of 46%. Responding patients showed striking improvements in marrow cell abnormalities as characterized by flow cytometry. These data show that a combination of ATG plus etanercept offers effective palliative therapy for unselected patients with MDS. Further trials incorporating these two agents are warranted.
Authors:
H Joachim Deeg; Peter Y Z Jiang; Leona A Holmberg; Bart Scott; Effie W Petersdorf; Frederick R Appelbaum
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia research     Volume:  28     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-09-21     Completed Date:  2004-11-16     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1177-80     Citation Subset:  IM    
Affiliation:
Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., D1-100, PO Box 19024, Seattle, WA 98109-1024, USA. jdeeg@fhcrc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilymphocyte Serum / therapeutic use*
Humans
Immunoglobulin G / therapeutic use*
Myelodysplastic Syndromes / drug therapy,  pathology,  therapy*
Pilot Projects
Receptors, Tumor Necrosis Factor / therapeutic use*
Grant Support
ID/Acronym/Agency:
CA87948/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antilymphocyte Serum; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein
Comments/Corrections
Comment In:
Leuk Res. 2004 Nov;28(11):1123-4   [PMID:  15380334 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association between phenotypic features of blasts and the blast percentage in bone marrow of patient...
Next Document:  Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to t...